News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

August 28, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2019 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 16, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2019 Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
July 26, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 22, 2019 Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
July 18, 2019 Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
July 8, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 27, 2019 Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
June 15, 2019 Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress